Evaluation of T-activated proteins as recall antigens to monitor Epstein–Barr virus and human cytomegalovirus-specific T cells in a clinical trial setting

Table 1 Response rates to EBV and HCMV T-activated proteins and peptide pools

Antigen	PBMC specimen	T-cell population	TP-induced reactivity (%)^a	PP-induced reactivity (%)^a
EBV-BZLF1	Fresh	CD4	87	77
	Cryo	CD4	77	70
	Fresh	CD8	73	80
	Cryo	CD8	67	87
EBV-EBNA3A	Fresh	CD4	73	87
	Cryo	CD4	87	77
	Fresh	CD8	90	87
	Cryo	CD8	80	77
HCMV-IE1	Fresh	CD4	94	89
	Cryo	CD4	83	83
	Fresh	CD8	94	100
	Cryo	CD8	72	94
HCMV-pp65	Fresh	CD4	95	100
	Cryo	CD4	95	100
	Fresh	CD8	95	95
	Cryo	CD8	74	100

^aReactivity defines the percentage of reactive donors after stimulation of freshly or cryopreserved PBMC of EBV- and HCMV-seropositive donors with the respective antigens

ISSN: 1479-5876